Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inspire Medical Systems's enterprise value is €1,256.2 Mil.
Inspire Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €68.0 Mil. Therefore, Inspire Medical Systems's EV-to-EBITDA for today is 18.47.
The historical rank and industry rank for Inspire Medical Systems's EV-to-EBITDA or its related term are showing as below:
STU:2DR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -556.77 Med: -60.94 Max: 387.41
Current: 18.19
During the past 11 years, the highest EV-to-EBITDA of Inspire Medical Systems was 387.41. The lowest was -556.77. And the median was -60.94.
STU:2DR's EV-to-EBITDA is ranked worse than 60.08% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.76
vs STU:2DR: 18.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Inspire Medical Systems (STU:2DR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inspire Medical Systems's PE Ratio (TTM) for today is calculated as:
Inspire Medical Systems's share price for today is €51.50.
Inspire Medical Systems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.942.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2DR vs AHCO, IART, CNMD: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Inspire Medical Systems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspire Medical Systems EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inspire Medical Systems's EV-to-EBITDA falls into.
Inspire Medical Systems's current Enterprise Value is €1,256.2 Mil.
Inspire Medical Systems's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €68.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspire Medical Systems (STU:2DR) has a EV-to-EBITDA of 18.47 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspire Medical Systems. According to the industry distribution chart, Inspire Medical Systems ranks #310 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 60.1%.
Is Inspire Medical Systems' EV-to-EBITDA too high?
Inspire Medical Systems' current EV-to-EBITDA is 18.47. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.76. Inspire Medical Systems' value of 18.47 is 25.1% above this industry median. Based on the distribution chart, Inspire Medical Systems ranks #310 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Inspire Medical Systems has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Inspire Medical Systems' EV-to-EBITDA compare to AHCO and IART?
According to the Medical Devices & Instruments industry distribution chart, Inspire Medical Systems ranks #310 out of 516 companies for EV-to-EBITDA. This places Inspire Medical Systems in the lower half of its industry. The industry median EV-to-EBITDA is 14.76. Inspire Medical Systems' value of 18.47 is 25.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.76, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspire Medical Systems's current EV-to-EBITDA of 18.47 is 25.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspire Medical Systems. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspire Medical Systems's current EV-to-EBITDA is 18.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Inspire Medical Systems (STU:2DR) is currently considered Significantly Undervalued. The stock's GF Value™ is €171.76, compared to a current price of €51.50 — trading 70% below its estimated fair value. The current EV-to-EBITDA is 18.47 and 25.1% above the Medical Devices & Instruments industry median of 14.76. Inspire Medical Systems' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Inspire Medical Systems (STU:2DR), the current EV-to-EBITDA is 18.47 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspire Medical Systems (STU:2DR) Overvalued in 2026?
Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued.
The current stock price of €51.50 is trading 70% below its estimated GF Value™ of €171.76.
GuruFocus considers Inspire Medical Systems to be Significantly Undervalued.
Key valuation signals for STU:2DR:
EV-to-EBITDA: 18.47
GF Value™: €171.76 vs. price of €51.50 (70% below fair value)
Industry Position: 25.1% above the Medical Devices & Instruments median (#310 of 516)
No single metric tells the full story. See the STU:2DR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
68GF Score
Get the complete analysis for STU:2DR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2DR has been successfully added to your 
